


Claims

- 5 1. A compound of formula (I)




(I)

wherein

Z is CH or N;

- 10 | G is cyano, ~~C(O)NR₁₅R₁₆, C(O)OR₁₇, C(O)R₂₁, C(CH₃)=NOR₂₂~~ or a group of formula



- 15 wherein A is a phenyl ring or a 5-12 membered heterocyclic ring, and
 R₁ is H, C₁₋₇ alkyl, C₃₋₇ cycloalkyl, C₃₋₇ cycloalkyl C₁₋₇ alkyl, C₁₋₇ alkoxy, C₁₋₇ alkyl carbonyl, amino, hydroxy, hydroxy C₁₋₇ alkyl, C₁₋₇ alkylamino C₁₋₇ alkyl, phenyl C₁₋₇ alkoxy, -NHC(O)-R₂₁, -R₁₂-C(O)-R₁₃, -SO₂-R₁₄ or -E-R₆, and
 R₂ is H, halogen, C₁₋₇ alkyl or oxo;
 20 B is a 5-12 membered carbocyclic or heterocyclic ring;
 R₃ is H, halogen, C₁₋₇ alkyl, C₁₋₇ alkoxy, cyano or an optionally substituted 5-6 membered heterocyclic ring;
 R₄ is H, halogen, C₁₋₇ alkyl or oxo;
 M is hydroxyl, C₁₋₇ alkyl or -NHR₅;

R₅ is H, -C(O)R₇, -SO₂R₈, -C(O)-D-R₉ or an optionally substituted 5-6 membered heterocyclic ring;

R₆ is an optionally substituted 5-6 membered heterocyclic ring;

5 R₇ is C₁₋₇ alkyl, C₂₋₇ alkenyl, C₃₋₇ cycloalkyl, C₁₋₇ alkoxy, C₁₋₇ alkoxy C₁₋₇ alkyl, carboxy C₁₋₇ alkyl, C₁₋₇ alkoxy carbonyl C₁₋₇ alkyl, C₁₋₇ alkylamino C₁₋₇ alkyl, -NH-R₁₀ or -NH-X₁-R₁₁;

R₈ is C₁₋₇ alkyl, C₂₋₇ alkenyl, C₃₋₇ cycloalkyl, hydroxy C₁₋₇ alkyl, -NR₁₈R₁₉, -NH-X₂-R₂₀, phenyl or an optionally substituted 5-6 membered heterocyclic ring;

R₉ is phenyl or an optionally substituted 5-6 membered heterocyclic ring;

10 R₁₀ is C₁₋₇ alkyl or C₃₋₇ cycloalkyl;

R₁₁ is phenyl or an optionally substituted 5-6 membered heterocyclic ring;

R₁₂ and R₂₁ are C₁₋₇ alkyl;

R₁₃ is C₁₋₇ alkoxy, amino or hydroxy;

R₁₄ is C₁₋₇ alkyl or C₃₋₇ cycloalkyl;

15 ~~R₁₅, R₁₆, R₁₇, R₁₈ and R₁₉ are, independently, H, C₁₋₇ alkyl or C₃₋₇ cycloalkyl;~~

R₂₀ is phenyl or an optionally substituted 5-6 membered heterocyclic ring;

~~R₂₁ is an optionally substituted 5-6 membered heterocyclic ring;~~

~~R₂₂ is H or C₁₋₇ alkyl;~~


E is a bond or a C₁₋₇ alkyl;

20 D is a bond or a C₁₋₇ alkyl;

X₁ and X₂ are, independently, a bond or C₁₋₇ alkyl;

and pharmaceutically acceptable salts thereof.


~~2. A compound according claim 1, wherein G is a group of formula~~




25

~~32. A compound according claim 1-~~or~~ 2, wherein M is -NHR₅.~~

~~43. A compound according to any of claims 1-32, wherein ring A is any one of the following groups or tautomers thereof~~



54. A compound according to any of claims 1 - 43, wherein ring B is any one of the following groups or tautomers thereof




65. A compound according to any of claims 1 to 54, wherein Z is CH.

76. A compound according to any of claims 1 to 54, wherein Z is N.

87. A compound according to any of claims 1 to 76, wherein

G is a group of formula



wherein A is a ring of formula (1'), (2'), (3'), (4'), (5'), (7'), (10'), (12'), (14'), (16') or (20');


5 R₁ is H, C₁₋₇ alkyl, C₁₋₇ alkoxy, hydroxy C₁₋₇ alkyl, C₁₋₇ alkylamino C₁₋₇ alkyl or -E-R₆;

R₂ is H;

B is a ring of formula (1''), (2''), (3''), (4'') or (6'');

E is a bond or C₁₋₇ alkyl;

10 R₆ is any of the following groups




R₃ is H, halogen, C₁₋₇ alkyl, C₁₋₇ alkoxy or cyano;

R₄ is H or halogen;


15 M is -NHR₅;

R₅ is -C(O)R₇, -SO₂R₈ or -C(O)-D-R₉ or any one of the following groups




R₇ is C₁₋₇ alkyl, C₂₋₇ alkenyl, -NH-R₁₀ or -NH-X₁-R₁₁;

20 R₈ is C₁₋₇ alkyl, C₂₋₇ alkenyl, C₃₋₇ cycloalkyl, hydroxy C₁₋₇ alkyl, -NR₁₈R₁₉, -NH-X₂-R₂₀, phenyl or a group




R₉ is phenyl or a any one of the following groups




R_{10} is C_{1-7} alkyl or C_{3-7} cycloalkyl;

5 R_{11} is phenyl, 4-fluorophenyl, or any one of the following groups



R_{18} and R_{19} are, independently, H, C_{1-7} alkyl or C_{3-7} cycloalkyl;

10 R_{20} is a group



X_1 and X_2 are, independently, a bond or C_{1-7} alkyl, and

D is a bond or C_{1-7} alkyl.

15 98. A compound according to any of claims 1 to 87, wherein B is a ring of formula (1'') or (6'').

109. A compound according to any of claims 1 to 98, wherein A is a ring of formula (1'), (2'), (4'), (7'), (10'), (14'), (16') or (20').

110. A compound according to any of claims 1 to 109, wherein B is phenyl, R_3 is halogen and R_4 is H or halogen.

20 1211. A compound according to any of claims 1 to 110, wherein M is -NHC(O) R_7 , wherein R_7 is C_{1-7} alkyl, C_{2-7} alkenyl, C_{3-7} cycloalkyl, -NH- R_{10} or -NH- X_1 - R_{11} , wherein R_{10} is C_{1-7} alkyl or C_{3-7} cycloalkyl, X_1 is a bond or C_{1-7} alkyl, and R_{11} is a 5-6 membered heterocyclic ring optionally substituted by one or two C_{1-7} alkyl groups.

25 1312. A compound according to any of claims 1 to 110, wherein M is -NHSO₂ R_8 wherein R_8 is C_{1-7} alkyl, C_{2-7} alkenyl, C_{3-7} cycloalkyl, phenyl, or NR₁₈ R_{19} wherein R_{18} and R_{19} are, independently, H, C_{1-7} alkyl or C_{3-7} cycloalkyl.

1413. A compound according to any of claims 1 to 1410, wherein M is -
NHC(O)-D-R₉ wherein D is bond or C₁₋₇ alkyl, and R₉ is a 5-6 membered heterocyclic
5 ring optionally substituted by one or two C₁₋₇ alkyl groups.
1514. A compound according to any of claims 1 to 1410, wherein R₅ is a 5-6
membered heterocyclic ring optionally substituted by one or two C₁₋₇ alkyl groups.
1615. A pharmaceutical composition comprising a compound of formula (I) or a
pharmaceutically acceptable salt thereof together with a pharmaceutically acceptable
10 carrier.
- ~~17. Use of a compound of formula (I) or a pharmaceutically acceptable salt
thereof in the manufacture of a medicament for the treatment of a condition, where
EGFR kinase inhibition is desired.~~
- ~~18. Use of a compound of formula (I) or a pharmaceutically acceptable salt
15 thereof in the manufacture of a medicament for the treatment of cancer.~~